Page 53 - 2020Taiwan Food and Drug Administration Annual Report

FKLHYHPHQWV DQG %HQH¿WV
$
$FKLHYHPHQWV DQG %HQH¿WV
I. Facilitated Taiwan's pharmaceutical exchange and the development of the
biotechnology and pharmaceutical industry
By collecting information on relevant laws and regulations of ASEAN countries and
hosting the two-day “2019 Taiwan-ASEAN Drug Regulatory Symposium,” TFDA facilitated the
industry to communicate with the representatives of the regulatory authorities of participating
ASEAN countries on the various issues of the application of pharmaceutical products. There
ZHUH D WRWDO RI LQGXVWU\ SDUWLFLSDQWV MRLQLQJ WKH H[FKDQJHV ZLWK RI¿FLDOV IURP 0DOD\VLD WKH
Philippines, Thailand, and Japan. TFDA promoted good communication with ASEAN countries

through exchange activities, establishing contact channels, and information sharing, and leads
the domestic pharmaceutical industry to have more opportunities for developing the market in
the New Southbound countries.

,, 6WUHQJWKHQHG WKH LQWHUDFWLRQ IRU WKH FHUWL¿FDWLRQ V\VWHP EHWZHHQ WHVWLQJ
institutions
In order to enhance the mutual understanding between Taiwan and the ASEAN countries
in the management and certification system of drug inspection institutions, we assess the
GLIIHUHQFHV EHWZHHQ WKH WZR SDUWLHV DQG ¿JXUH RXW WKH SRVVLELOLW\ RI PXWXDO DFFHSWDQFH UHJDUGLQJ
certification between Taiwan and ASEAN countries. We could reduce unnecessary trading
costs, increase the quality and circulation of medical products, and promote the development of
Taiwan's drug testing institutions and related manufacturers to catch the opportunities in ASEAN

countries with the premise that consumers are safe.

'JHVSF cc4FNJOBS PO /FX 4PVUICPVOE $PVOUSJFT 1IBSNBDFVUJDBM 1SPEVDUT (-1 3FHVMBUJPOT
BOE 1SJODJQMF 51